Drug Trial Radar · NCT01283061
Bioequivalence Study of Zafirlukast Tablets 20 mg of Dr. Reddy's Laboratories Limited Under Fasting Condition
Last checked: Nov 20, 2026Latest source record: Jan 26, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
44
Actual
Start
Dec 2007
Primary completion
Jan 2008
Study completion Jan 2008
Sponsor
- Lead sponsor
- Dr. Reddy's Laboratories Limited, IndiaIndustry
- Sponsor type
- Industry
- First posted
- Jan 25, 2011
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objective of this study was to compare the relative bioavailability of zafirlukast tablets 20 mg with that of 'ACCOLATE®' tablets 20 mg (zafirlukast tablets 20 mg) in healthy, adult, human, subjects under fasting conditions and to monitor safety of subjects.
Conditions
- Healthy
Interventions
ZafirlukastDrug
Zafirlukast tablets 20 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Bioequivalence on Cmax and AUC parametersTime frame: 13 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
BA Research India Ltd.
Ahmedabad, Bodakdev, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.